Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$68.97−5.36 (-7.21%)
Close on Nov 20, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Inhibrx Biosciences's revenue for the twelve months ending Dec 31, 2025 was $1.30M, up 550.0% year over year. For fiscal 2025 it was $1.30M, up 550.0% from the year before. The highest annual figure on record is $13.21M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30M | +550.0% |
| FY2024 | Dec 31, 2024 | $200.00K | -88.9% |
| FY2023 | Dec 31, 2023 | $1.80M | -17.9% |
| FY2022 | Dec 31, 2022 | $2.19M | -69.7% |
| FY2021 | Dec 31, 2021 | $7.23M | -43.9% |
| FY2020 | Dec 31, 2020 | $12.89M | -2.4% |
| FY2019 | Dec 31, 2019 | $13.21M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.00M | +53.8% |
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $1.30M | +1200.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $100.00K | -93.9% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $100.00K | +233.3% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.63M | +496.4% |
| Q3 FY2023 | Sep 30, 2023 | $119.00K | -57.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.00K | -95.8% |
| Q1 FY2023 | Mar 31, 2023 | $17.00K | -98.2% |
| Q4 FY2022 | Dec 31, 2022 | $274.00K | -90.4% |
| Q3 FY2022 | Sep 30, 2022 | $278.00K | -89.0% |
| Q2 FY2022 | Jun 30, 2022 | $711.00K | -25.5% |
| Q1 FY2022 | Mar 31, 2022 | $929.00K | +4.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.86M | +2.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.53M | -57.1% |
| Q2 FY2021 | Jun 30, 2021 | $954.00K | -71.4% |
| Q1 FY2021 | Mar 31, 2021 | $889.00K | +1.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.78M | +955.5% |
| Q3 FY2020 | Sep 30, 2020 | $5.90M | +384.1% |
| Q2 FY2020 | Jun 30, 2020 | $3.34M | – |
| Q1 FY2020 | Mar 31, 2020 | $872.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $263.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $1.22M | – |
See a number that looks wrong?